Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
The present invention provides methods for optimizing clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. The methods of the present invention may further comprise determining the level of at least one long-chain methotrexate polyglutamate (MTXPG) in a sample obtained from the individual. The present invention also provides methods for generating a pharmacogenetic index for predicting clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. In addition, the present invention provides methods for optimizing therapeutic efficacy of chemotherapy in an individual by calculating the level of at least one long-chain MTXPG in a sample obtained from the individual.
1. A method for optimizing therapeutic efficacy of methotrexate (MTX) therapy in an individual receiving MTX, wherein said individual has an autoimmune disease, said method comprising:
determining the concentration level of MTXPG 3 in a red blood cell sample from said individual, wherein a concentration level of said MTXPG 3 less than about 60 nmol/L is indicative of a need to increase the amount of MTX subsequently administered to said individual.
2. The method of claim 1 , wherein said individual has rheumatoid arthritis.
3. The method of claim 1 , wherein said MTXPG 3 is resolved chromatographically.
4. The method of claim 3 , wherein the concentration level of said MTXPG 3 is determined using a technique selected from the group consisting of fluorimetry, spectrophotometry, and mass spectrometry.
5. A method for determining clinical responsiveness to methotrexate (MTX) therapy in an individual receiving MTX, wherein said individual has an autoimmune disease, said method comprising:
determining the concentration level of MTXPG 3 in a red blood cell sample from said individual, wherein a concentration level of said MTXPG 3 greater than about 60 nmol/L is indicative of superior clinical responsiveness to said MTX therapy.
6. The method of claim 5 , wherein said individual has rheumatoid arthritis.
7. The method of claim 5 , wherein said MTXPG 3 is resolved chromatographically.
8. The method of claim 7 , wherein the concentration level of said MTXPG 3 is determined using a technique selected from the group consisting of fluorimetry, spectrophotometry, and mass spectrometry.
9. A method for determining clinical responsiveness to methotrexate (MTX) therapy in an individual receiving MTX, wherein said individual has an autoimmune disease, said method comprising:
determining the concentration level of MTXPG 3 in a red blood cell sample from said individual, wherein a concentration level of said MTXPG 3 less than about 40 nmol/L is indicative of inferior clinical responsiveness to said MTX therapy.
10. The method of claim 9 , wherein said individual has rheumatoid arthritis.
11. The method of claim 9 , wherein said MTXPG 3 is resolved chromatographically.
12. The method of claim 11 , wherein the concentration level of said MTXPG 3 is determined using a technique selected from the group consisting of fluorimetry, spectrophotometry, and mass spectrometry.
13. The method of claim 1 , 5 , or 9 , wherein MTXPG 3 is resolved by HPLC.
14. A method for optimizing therapeutic efficacy of methotrexate (MTX) therapy in an individual receiving MTX, wherein said individual has an autoimmune disease, said method comprising:
determining the concentration level of MTXPG 3-5 in a red blood cell sample from said individual, wherein a concentration level of said MTXPG 3-5 less than about 90 nmol/L is indicative of a need to optimize said MTX therapy.
15. The method of claim 14 , wherein said individual has rheumatoid arthritis.
16. The method of claim 14 , wherein said MTXPG 3-5 is resolved chromatographically.
17. The method of claim 14 , wherein said MTXPG 3-5 is resolved by HPLC.
18. The method of claim 16 , wherein the concentration level of said MTXPG 3-5 is determined using a technique selected from the group consisting of fluorimetry, spectrophotometry, and mass spectrometry.
19. A method for determining clinical responsiveness to methotrexate (MTX) therapy in an individual receiving MTX, wherein said individual has an autoimmune disease, said method comprising:
determining the concentration level of MTXPG 3-5 in a red blood cell sample from said individual, wherein a concentration level of said MTXPG 3-5 greater than about 90 nmol/L is indicative of clinical responsiveness to said MTX therapy.
20. The method of claim 19 , wherein said individual has rheumatoid arthritis.
21. The method of claim 19 , wherein said MTXPG 3-5 is resolved chromatographically.
22. The method of claim 19 , wherein said MTXPG 3-5 is resolved by HPLC.
23. The method of claim 21 , wherein the concentration level of said MTXPG 3-5 is determined using a technique selected from the group consisting of fluorimetry, spectrophotometry, and mass spectrometry.
24. A method for determining clinical responsiveness to methotrexate (MTX) therapy in an individual receiving MTX, wherein said individual has an autoimmune disease, said method comprising:
determining the concentration level of MTXPG 3-5 in a red blood cell sample from said individual, wherein a concentration level of said MTXPG 3-5 less than about 55 nmol/L is indicative of inferior clinical responsiveness to said MTX therapy.
25. The method of claim 24 , wherein said individual has rheumatoid arthritis.
26. The method of claim 24 , wherein said MTXPG 3-5 is resolved chromatographically.
27. The method of claim 24 , wherein said MTXPG 3-5 is resolved by HPLC.
28. The method of claim 26 , wherein the concentration level of said MTXPG 3-5 is determined using a technique selected from the group consisting of fluorimetry, spectrophotometry, and mass spectrometry.